DLD Asset Management LP Makes New Investment in Trevi Therapeutics, Inc. $TRVI

DLD Asset Management LP bought a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 55,000 shares of the company’s stock, valued at approximately $503,000.

Several other institutional investors also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Trevi Therapeutics by 4.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock worth $195,000 after buying an additional 911 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Trevi Therapeutics by 20.5% in the third quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock valued at $70,000 after acquiring an additional 1,300 shares during the last quarter. Persistent Asset Partners Ltd grew its holdings in Trevi Therapeutics by 3.3% during the 2nd quarter. Persistent Asset Partners Ltd now owns 42,788 shares of the company’s stock worth $234,000 after acquiring an additional 1,384 shares during the period. BIT Capital GmbH grew its holdings in Trevi Therapeutics by 32.0% during the 3rd quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock worth $62,000 after acquiring an additional 1,633 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its position in shares of Trevi Therapeutics by 20.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 12,000 shares of the company’s stock valued at $66,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Stock Up 1.7%

Shares of NASDAQ TRVI opened at $13.30 on Monday. Trevi Therapeutics, Inc. has a twelve month low of $4.24 and a twelve month high of $14.39. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -35.94 and a beta of 0.94. The company’s fifty day moving average is $11.26 and its 200-day moving average is $10.73.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TRVI. B. Riley Financial raised Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Stifel Nicolaus upped their price objective on Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Oppenheimer raised their target price on Trevi Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Finally, Leerink Partners boosted their target price on Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and a consensus price target of $21.10.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.